This page lists the SEC filings reported by Novo Holdings A/S.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2022-09-30 | Novo Holdings A/S | Edgewise Therapeutics, Inc. | 6,071,703 | 9.6% | EDGAR |
| SC 13D/A | 2022-09-30 | Novo Holdings A/S | Bolt Biotherapeutics, Inc. | 3,703,991 | 9.8% | EDGAR |
| SC 13D/A | 2022-09-30 | Novo Holdings A/S | IO Biotech, Inc. | 3,277,932 | 11.4% | EDGAR |
| SC 13D/A | 2022-09-30 | Novo Holdings A/S | Galecto, Inc. | 2,497,791 | 9.8% | EDGAR |
| SC 13D/A | 2022-09-30 | Novo Holdings A/S | SPRUCE BIOSCIENCES, INC. | 4,514,336 | 19.2% | EDGAR |
| SC 13D/A | 2022-09-26 | Novo Holdings A/S | Milestone Pharmaceuticals Inc. | 2,097,713 | 7.0% | EDGAR |
| SC 13D/A | 2022-09-16 | Novo Holdings A/S | Edgewise Therapeutics, Inc. | 6,071,703 | 9.6% | EDGAR |
| SC 13D/A | 2022-08-18 | Novo Holdings A/S | Mirum Pharmaceuticals, Inc. | 1,760,000 | 4.8% | EDGAR |
| SC 13D/A | 2022-08-02 | Novo Holdings A/S | Mirum Pharmaceuticals, Inc. | 1,889,127 | 5.9% | EDGAR |
| SC 13D/A | 2022-07-25 | Novo Holdings A/S | Cyteir Therapeutics, Inc. | 3,940,413 | 11.1% | EDGAR |
| SC 13D/A | 2022-07-15 | Novo Holdings A/S | Bolt Biotherapeutics, Inc. | 3,703,991 | 9.8% | EDGAR |
| SC 13D/A | 2022-06-03 | Novo Holdings A/S | Nkarta, Inc. | 2,238,309 | 4.6% | EDGAR |
| SC 13D/A | 2022-06-03 | Novo Holdings A/S | Checkmate Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2022-05-26 | Novo Holdings A/S | IO Biotech, Inc. | 3,277,932 | 11.3% | EDGAR |
| SC 13D/A | 2022-05-11 | Novo Holdings A/S | Checkmate Pharmaceuticals, Inc. | 1,828,484 | 8.3% | EDGAR |
| SC 13D/A | 2022-05-02 | Novo Holdings A/S | Nkarta, Inc. | 2,238,309 | 6.7% | EDGAR |
| SC 13D/A | 2022-04-08 | Novo Holdings A/S | Mirum Pharmaceuticals, Inc. | 2,200,000 | 6.9% | EDGAR |
| SC 13D/A | 2022-02-22 | Novo Holdings A/S | Morphic Holding, Inc. | 1,845,030 | 4.9% | EDGAR |
| SC 13G | 2022-02-09 | Novo Holdings A/S | Arcellx, Inc. | 4,016,878 | 11.4% | EDGAR |
| SC 13G/A | 2022-02-02 | Novo Holdings A/S | Galera Therapeutics, Inc. | 2,459,021 | 9.3% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.